Effectiveness of Agomelatine in Generalized Anxiety Disorder Comorbid to Bipolar 1 Disorder in a Male Adolescent Patient
- 12 August 2024
- journal article
- case report
- Published by Wolters Kluwer Health in Clinical Neuropharmacology
- Vol. 47 (5) , 143-145
Abstract
Anxiety comorbidity in bipolar disorder (BD) is important and thus significantly affects the course of BD and its outcomes. The treatment of generalized anxiety disorder comorbid with BD involves certain challenges, as antidepressant medications, which are standard in the treatment of anxiety disorder, have the risk of shifting to manic episodes and rapid cycling. In this case report, the response to agomelatine treatment in generalized anxiety disorder comorbid with bipolar 1 disorder was evaluated.Keywords
This publication has 22 references indexed in Scilit:
- Advances in Pharmacotherapy for Pediatric Anxiety DisordersChild and Adolescent Psychiatric Clinics of North America, 2023
- Bipolar disordersThe Lancet, 2020
- The role of lifetime anxiety history in the course of bipolar spectrum disordersPsychiatry Research, 2018
- Efficacy and Safety of Lurasidone in Children and Adolescents With Bipolar I Depression: A Double-Blind, Placebo-Controlled StudyJournal of the American Academy of Child & Adolescent Psychiatry, 2017
- Psychopharmacology of Bipolar Disorders in Children and AdolescentsPediatric Clinics of North America, 2017
- The bipolarity of light and dark: A review on Bipolar Disorder and circadian cyclesJournal of Affective Disorders, 2015
- Prevalence and Correlates of Bipolar Spectrum Disorder in the World Mental Health Survey InitiativeArchives of General Psychiatry, 2011
- Agomelatine, the first melatonergic antidepressant: discovery, characterization and developmentNature Reviews Drug Discovery, 2010
- Functional impact of biological rhythm disturbance in bipolar disorderJournal of Psychiatric Research, 2010
- Comorbidity in Pediatric Bipolar DisorderChild and Adolescent Psychiatric Clinics of North America, 2009